MULTICELL TECHNOLOGIES
68 Cumberland Street
Suite 301
Woonsocket, RI 02895
R &D / clinical-stage biopharmaceutical company
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and certain cancers.
Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.
MCET's therapeutic development platform offers several key advantages:
Selective modulation of noradrenergic neurons without influencing seratoninergic neurons to inhibit the reuptake of noradrenaline (norepinephrine) while promoting increased tyrosine hydroxylase activity for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis (MS).
Unlike other immune modulating compounds, our use of novel synthetic dsRNAs is not species or sequence-specific yet enables selective control of critical immune signaling pathways, and therefore has the potential in a broader spectrum of therapeutic applications as a monotherapy or in combination with other therapies.
Coupling our synthetic double stranded RNA (dsRNA) platform technology with our therapeutic antibody technology, maximizes the potential of disease-associated epitope peptides to create a novel class of more effective anticancer therapeutics.
The potential to isolate cancer stem cells from human liver in support of the development of novel therapeutics needed to effectively manage and treat patients with primary hepatocellular carcinoma.
MCET's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development:
MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
The Xenogenics subsidiary has rights to a unique cardiac stent.
Partnerships are sought.
Keywords: pharmaceutical, therapeutics,
Customer Reviews for MULTICELL TECHNOLOGIES
Be the first to review MULTICELL TECHNOLOGIES - Use the thumbs to get started!
Click to Rate:
0 thumbs up, 0 thumbs down
Interview Q&A
How long have you been in business?
46 years.
What is your primary product or service?
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address the needs for the treatment of neurological disorders, hepatic disease and cancer. Our Xenogenics subsidiary has a patented cardiac stent. Our MCTI subsidiary recently signed an antibody-drug conjugate R&D, product license and commercialization agreement with Oxis.
How did you first become interested in your line of business? (if owner) - What is your background? (If owner or store manager)
CEO, Jerry Newmin - I had a life-long career as a successful crisis management guy. I started by turning around troubled companies and divisions for Whittaker Corporation in the 60s, I restructured the International Silver Company, managed more than 20 hospitals for American Medicorp and more than 40 health plans for HealthAmerica. I helped found the Corporate Directors Forum in San Diego, CA and was Director of the Year in 1999 for my role in rejuvenating that corporate governance organization.
I took over MultiCell Technologies in 1997 when it went by a previous name, and have gotten personally involved in the company's evolution to a multi-subsidiary company with multiple potential therapeutics for unmet medical needs.
How do you differentiate yourself from other businesses in your category and area?
Our therapeutic development platform relies on several patented technologies used to: (i) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (ii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iii) modulate the noradrenaline-adrenaline neurotransmitter pathway. isolate and (iv) characterize and differentiate stem cells from human liver,
How many locations do you have and do you have plans to expand?
Our research is conducted in the UK, Canada and the US. The RI office is corporate headquarters.
Provide detailed directions to your location
68 Cumberland St. Suite 301
Woonsocket, RI 02895
What type of payments do you accept?
$
Which areas do you service?
Interntional.
Who owns your company or runs daily operations?
It's a publicly traded company.
What are your hours of operation?
9 - 5
What is the best compliment anyone can give you?
I'd like to hear "Wow, is your stock undervalued!"
What is your favorite quote or Bible verse?
The Golden rule!
Contact MULTICELL TECHNOLOGIES:
Problem with this listing? Please report it